Stem cell 'cure' boy gets tumour
By BBC,
BBC News
| 02. 18. 2009
A boy treated with foetal stem cells for a rare genetic disease has developed benign tumours, raising questions about the therapy's safety.
The boy, now 17, received the stem cells in 2001 at a Moscow hospital and four years later scans showed brain and spinal tumours, PLoS Medicine reports.
Israeli doctors removed the abnormal growth from his spine and tests suggest it sprouted from the stem cells.
Critics say the finding is evidence against the controversial therapy.
Apart from the ethics of using cells taken from embryos, opponents say there are big safety concerns.
As well as the possibility that stem cells may turn cancerous, some researchers fear that it is possible that stem cell therapy could unwittingly pass viruses and other disease causing agents to people who receive cell transplants.
Experimental therapy
Experts are hopeful that stem cells, which have the ability to develop into other kinds of human cells, will eventually lead to treatments for some of the most intractable conditions.
The boy in question was treated for a condition called Ataxia Telangiectasia - a genetic disease that...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
